Eli Lilly to Buy Biotech Orna Therapeutics for Up to $2.4 Billion

Core Insights - Eli Lilly has agreed to acquire Orna Therapeutics, a genetic-medicine biotechnology company, for a total consideration of up to $2.4 billion in cash [1] Company Summary - The acquisition reflects Eli Lilly's strategic focus on expanding its capabilities in genetic medicine [1] - Orna Therapeutics specializes in innovative genetic therapies, which aligns with Eli Lilly's growth objectives in the biotechnology sector [1] Financial Implications - The deal is valued at up to $2.4 billion, indicating a significant investment by Eli Lilly in the biotechnology space [1]